StockNews.com Begins Coverage on Aspira Women’s Health (NASDAQ:AWH)

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report released on Monday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners reduced their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Aspira Women’s Health stock opened at $0.75 on Monday. Aspira Women’s Health has a 12 month low of $0.67 and a 12 month high of $5.65. The company has a market capitalization of $12.50 million, a price-to-earnings ratio of -0.62 and a beta of 1.44. The business’s fifty day simple moving average is $0.84 and its two-hundred day simple moving average is $1.29.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. 12.19% of the stock is currently owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.